MO25 Inhibitors

The chemical class of MO25 Inhibitors primarily focuses on modulating the AMPK pathway, as MO25 is intricately linked with this energy-sensing kinase complex. The AMPK complex, consisting of the catalytic α subunit and the regulatory β and γ subunits, is activated in response to cellular stressors that deplete ATP, such as glucose deprivation or hypoxia. MO25, as a scaffold protein, enhances the phosphorylation and activation of the LKB1-AMPK pathway, playing a pivotal role in cellular energy homeostasis.

The inhibitors listed are predominantly ATP-competitive inhibitors or activators of AMPK. By influencing AMPK activity, these chemicals indirectly affect MO25's function. For example, Compound C and BML-275 (Dorsomorphin) inhibit AMPK, potentially altering the recruitment or stabilization of MO25 within the AMPK complex. Similarly, activators like A-769662 and Metformin can lead to changes in AMPK activity that indirectly modulate MO25's role. In addition to direct AMPK modulators, some chemicals like GSK690693 target downstream pathways, in this case, the AKT pathway. By modulating downstream signaling events, these inhibitors can indirectly influence the biological functions in which MO25 is involved. STO-609, by inhibiting CaMKK, affects an upstream kinase of AMPK, demonstrating another approach to indirectly influencing MO25's activity.